A randomized, double-blind, placebo-controlled, phase 2 study of S-033188 in otherwise healthy adult patients with influenza
Latest Information Update: 26 May 2022
At a glance
- Drugs Baloxavir-marboxil (Primary)
- Indications Influenza virus infections
- Focus Proof of concept; Registrational; Therapeutic Use
- Sponsors Shionogi
- 18 May 2022 Results by deriving data from JapicCTI-153090, NCT02954354; NCT02949011, NCT03959332; KCT0003535, developing pharmacokinetics-time to alleviation of symptoms (PK-TTAS) model to study Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B.published in the Clinical Pharmacology and Therapeutics
- 24 Jun 2021 Results of comparative analysis of baloxavir pharmacokinetics and simulated efficacy in chinese individuals and asian patients by using data of baloxavir clinical trials (a Phase I study (NCT03959332), a Phase II study (OwH; T0821), and Phase III studies in OwH (NCT02954354) and high risk (NCT02949011)), presented at the World Microbe Forum 2021
- 29 Aug 2019 According to an Shionogi media release, the company announced that Xofluza has been approved in Taiwan for the treatment of acute influenza Types A and B in patients 12 years of age and older on August 28, 2019.